SUMMARY MDL 17,043 administered intravenously or orally exerts positive inotropic and vasodilator actions in experimental animal preparations. We studied its acute hemodynamic effects in 15 patients with severe congestive heart failure by right-heart catheterization. Intravenous MDL 17,043 at 10 minutes increased cardiac index (3.4 0.8 vs 1.9 0.4 1/min/m2), narrowed arteriovenous oxygen content difference (4.6 ± 0.8 vs 7.8 2.0 vol%), increased heart rate (98 ± 14 vs 89 ± 18 beats/min), and decreased systemic arterial (67 10 vs 83 ± 11 mm Hg), pulmonary capillary wedge (12 ± 5 vs 24 ± 5 mm Hg) and right atrial (6 ± 5 vs 12 ± 7 mm Hg) mean pressures significantly (p < 0.001). In 11 patients, hemodynamics were monitored hourly for 6 hours. Compared with baseline, the cardiac index and heart rate were higher and mean systemic arterial pressure was lower for 6 hours; pulmonary capillary and right atrial mean pressures were significantly lower for 5 hours. No serious arrhythmias or side effects occurred. These data suggest that MDL 17,043 may be useful for treating congestive heart failure.
THE CONCEPT that contractile strength, even of the end-stage myopathic ventricle, can be increased by enhancing the inotropic state of the myocardium has led to the search for a safer, more effective agent than digitalis for treating chronic congestive heart failure. One such prospect is MDL 17,043 (1, 3, dihydro-4-methyl-5 - [4 - (methylthio) benzoyl] -2H-imidazol-2-one) ( fig. 1) , which has been shown to possess significant inotropism in animal studies using isolated cardiac muscle strips, normal intact animal preparations, and a model of propranolol-induced heart failure.'-' MDL 17,043 also causes significant peripheral arterial vasodilation in the dog' and is effective both intravenously and orally.' Moreover, acute and chronic therapy with MDL 17,043 in various animal species has shown a remarkable lack of toxicity. For all these reasons, this agent holds hope for more effective oral therapy of heart failure.
In this study, we report the acute hemodynamic effects of i.v. MDL 17,043 in 15 patients.
Materials and Methods
Using a protocol approved by the Human Use Committee at our institution, we studied 15 patients with severe congestive heart failure uncontrolled by digitalis and diuretic therapy (table 1). All patients had cardiomegaly (cardiothoracic ratio > 50%) on chest x-ray. The causes of heart failure, documented by cardiac catheterization, were ischemic heart disease in five patients and corrected mitral regurgitation with residual left ventricular dysfunction in two; heart failure was idiopathic in four patients. Of the four remain-ing patients, three (nos. 9, 12 and 14) were in normal sinus rhythm, and radionuclide angiography revealed severe global hypokinesis. Patient 13 was in atrial fibrillation and the ejection fraction by radionuclide angiography was 39%.
The average age of the patients was 55 years. There were 11 men and four women. Nine patients had received various vasodilators, but the results were unsatisfactory and the patients were referred for study. In the six other patients, relative hypotension made the use of vasodilators too risky. Patients were excluded from the study under the following circumstances: systolic blood pressure less than 85 mm Hg, uncontrolled tachyarrhythmias, heart failure due to restrictive or hypertrophic cardiomyopathy or stenotic valvular disease, women of childbearing potential, and primary hepatic, hematologic, neurologic or renal disease.
All patients were taking digoxin chronically at the time of the study; the morning dose was withheld on the day of the study. Complete hemodynamic data were obtained over 6 hours in 11 patients (fig. 2) . The improvement in cardiac output was sustained (p < 0.001, control vs each hour) and was 49% higher than baseline at 6 hours. A similar response was seen in the increase in heart rate. Right atrial and pulmonary wedge pressures were significantly decreased for 5 hours, but had returned to baseline by the sixth hour. The mean systemic pressure remained lower than baseline for the entire 6 hours. The rise in left ventricular stroke work index was sig- nificant only at 10 minutes (table 1), but remained higher than the baseline for the duration of the study.
Only two patients received the full number of dosage increments ( fig. 3, patient 3) . The study was terminated in three patients before the full number of increments was given because cardiac output plateaued (< 10% increase) ( fig. 3, patient 4) , in six patients because pulmonary capillary wedge pressure fell below 10 mm Hg ( fig. 3, patient 1) , and in four patients because systolic arterial pressure fell by more than 20% or below 85 mm Hg. Figure 4 shows a stepwise increase in cardiac output with an increasing total cumulative dose. Similar qualitative stepwise changes with increasing doses of MDL 17,043 were seen in A-VO difference; right atrial, pulmonary arterial, systemic arterial and pulmonary capillary wedge pressures; left ventricular stroke work index; and heart rate.
There were no adverse reactions requiring termination of the study. Patient 8 had an episode of emesis during the last dose, but had this problem before the study. After a 15-minute rest, the infusion was completed and the study continued without incident. Patient 13 experienced 15 minutes of disorientation I hour after the last increment and 1.5 hours after 12.5 mg of i.v. diazepam was given for chronic leg cramps. Discussion MDL 17,043 produced a dramatic and sustained improvement in cardiac performance in these patients with severe decompensated heart failure. Cardiac output and stroke work index increased, and both rightand left-sided filling pressures decreased.
The hemodynamic improvement may have been due to vasodilation or increased inotropy. The significant decrease in systemic arterial pressure and resistance in association with a significant increase in cardiac output after MDL 17,043 is compatible with its arterial vasodilatory property. The relative contribution of the inotropic action of this drug to hemodynamic improvement is not resolved by this study, as is frequently the case in investigations in man of agents that have inotropic and vasodilator properties in experimental preparations.5'8 MDL 17,043 increases contractile force in isolated guinea pig and cat atria and feline left ventricular papillary muscle.' When systemic blood pressure and venous return were kept constant in the normal canine heart-lung preparation, cardiac contractile force increased progressively in a dose-dependent manner.2 Left atrial pressure also decreased without change in The mechanism of the hemodynamic effects of MDL 17,043 is not known. Neither the inotropic nor the vasodilator actions are blocked by ,3-or a-adrenergic antagonists, which suggests that sympathetic receptors are not important in either of its cardiovascular actions.' The contractile increase due to MDL 17,043 appears to be additive with ouabain, which suggests a different mechanism of action from that of the digitalis compounds.' The basic biochemical mechanism remains to be elucidated.
A small (10%) but significant rise in heart rate occurred in our patients. A dose-related increase in heart rate was observed in the anesthetized dog, and there was a 1:8 ratio between chronotropic and inotropic properties.' A similar response was seen in isolated, spontaneously beating feline right atria, but MDL 17,043 showed very little or no positive chronotropism in spontaneously beating guinea pig right atria.' Thus, this response appears to be, to some extent, speciesrelated. The rise in heart rate does not appear to be mediated through the /,3 receptor, for the administration of MDL 17,043 does not shift the chronotropic response to isoproterenol in the anesthetized dog,' nor is the heart rate increase inhibited by full blocking doses of propranolol. l MDL 17,043 may stimulate the sinoatrial node directly, particularly in view of the absence of an increase in heart rate characterized by vasodilators, which produce an otherwise similar hemodynamic profile.9-"
The duration of action of MDL 17,043 appears in experimental studies to be dose-related, and varies depending upon the variable measured. Thus, in the anesthetized dog, the increase in contractile force showed the longest duration, followed by changes in heart rate and blood pressure for each dose. ' An analogous situation occurred in our patient population. Changes in cardiac output, heart rate, and systemic arterial pressure were sustained for 6 hours, but pulmonary capillary wedge and right atrial pressures tended to return to baseline by 6 hours. This study does not show how long the cardiac output and heart rate remain elevated in response to MDL 17,043, because they were still significantly elevated at the end of 6 hours.
Oral studies in animals demonstrated a rapid onset of action (within 10 minutes) and maintenance of effect for 5 hours.' Thus, if the absorption and duration of action are similar in man, MDL 17,043 may be useful in the treatment of chronic congestive heart failure. Such chronic therapy requires that neither hemodynamic tolerance nor chronic toxicity occur. Hemodynamic effects in dogs have not been attenuated up to 9 days after institution of the agent.' Furthermore, in acute and chronic toxicity studies for up to 3 months in mice, rats and dogs, no significant organ damage or hematologic or biochemical abnormality has been observed. ' This preliminary study demonstrates the beneficial hemodynamic effects of MDL 17,043 when administered acutely. These promising results warrant further investigations, including more complete elucidation of the hemodynamic profile of the i.v. and oral preparations, the effect on myocardial oxygen consumption and regional blood flow, and, probably most important for the clinician, the chronic efficacy (by hemodynamic, functional, and clinical variables) of this agent.
Finally, we should consider whether any inotropic agent can chronically stimulate the failing heart and maintain improvement in cardiac function. Colucci et al. 12 demonstrated that when oral pirbuterol, an experimental vasodilator/inotrope, is given chronically, the improvement in ejection fraction disappears over time.'2 These disappointing data, however, must be balanced by studies of the withdrawal of digoxin '3 or amrinone'4 after several months of therapy. These studies showed that hemodynamics deteriorated after digoxin or amrinone therapy was stopped and improved upon reinstitution of therapy. Thus, it appears, at least with certain drugs, that chronic stimulation of the myocardium is possible with maintenance of he-827 VOL 67, No 4, APRIL 1983 modynamic and presumably clinical improvement. Further investigations into the actions of MDL 17,043 will determine its eventual place in the treatment of congestive heart failure.
